Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Author response to Colle et al.

Giovanni Fucà1, Francesca Corti1, Filippo Pietrantonio2

  • 1Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Journal for Immunotherapy of Cancer
|June 24, 2021
PubMed
Summary

Pseudoprogression is uncommon in MSI-high metastatic colorectal cancer patients on immune checkpoint inhibitors. Early disease re-assessment timing may increase pseudoprogression incidence, impacting treatment efficacy interpretation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.

Nature communications·2026
Same author

Amivantamab Monotherapy in Chemorefractory <i>RAS</i>/<i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Molecular lineages of sporadic mismatch-repair deficient colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Reply to: Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability-High Gastric Cancer: Solid Evidence or Premature Extrapolation?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.

Nature reviews. Clinical oncology·2026

Area of Science:

  • Oncology
  • Immunotherapy
  • Colorectal Cancer Research

Background:

  • Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment.
  • MSI-high metastatic colorectal cancer (mCRC) shows promise with ICIs.
  • Pseudoprogression, a rare event, can complicate treatment response assessment.

Purpose of the Study:

  • To address the incidence of pseudoprogression in MSI-high mCRC patients treated with ICIs.
  • To discuss the potential influence of disease re-assessment timing on pseudoprogression rates.
  • To provide context for interpreting treatment efficacy in this patient population.

Main Methods:

  • Response to a Letter to the Editor.
  • Analysis of pseudoprogression events in clinical context.
Keywords:
gastrointestinal neoplasmsimmunotherapytumor biomarkers

Related Experiment Videos

  • Review of disease re-assessment schedules.

    • Main Results:

    • Pseudoprogression is infrequently observed in MSI-high mCRC patients receiving ICIs.
    • Earlier disease re-assessment is associated with a higher observed incidence of pseudoprogression.
    • The timing of imaging and clinical evaluations is a critical factor.

    Conclusions:

    • The interpretation of pseudoprogression requires careful consideration of assessment timing.
    • Understanding these dynamics is crucial for accurate efficacy assessment of ICIs in mCRC.
    • Further research may explore optimal monitoring schedules.